R&D | October 29, 2025
Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Subscribe To Our Newsletter & Stay Updated
